PMGC updates MOA drug license milestones and timelines
PMGC Holdings Inc., through its wholly owned subsidiary Northstrive Biosciences Inc., entered into a Third Amendment to its License Agreement with MOA Life Plus Co., Ltd., effective March 24, 2026.
Rhea-AI Filing Summary
PMGC Holdings Inc., through its wholly owned subsidiary Northstrive Biosciences Inc., entered into a Third Amendment to its License Agreement with MOA Life Plus Co., Ltd., effective March 24, 2026. The amendment replaces Exhibit C, updating development milestones in the licensed field, including phases for pre-clinical trials, related Investigational New Drug application events, and the timelines for achieving these milestones. PMGC will provide monetary consideration to MOA in connection with entering this amendment, payable upon execution and within 30 days after the effective date.
Positive
- None.
Negative
- None.
8-K Event Classification
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did PMGC Holdings (ELAB) disclose in the March 24, 2026 filing?
Who are the parties to PMGC Holdings (ELAB) Third Amendment to the License Agreement?
How does the Third Amendment affect PMGC (ELAB) development milestones?
What is the effective date of PMGC Holdings (ELAB) Third Amendment with MOA?
Does PMGC Holdings (ELAB) owe consideration under the Third Amendment with MOA?
Where can investors find the full text of PMGC (ELAB) Third Amendment to the License Agreement?
AI-generated analysis. How Rhea-AI works. Not financial advice.